These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10890323)

  • 1. New drugs for hepatitis C virus (HCV).
    Clarke BE
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Apr; 14(2):293-305. PubMed ID: 10890323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and evolving therapies for hepatitis C.
    Moradpour D; Blum HE
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
    Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
    Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
    Zhu H; Butera M; Nelson DR; Liu C
    Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapies on the horizon for hepatitis C: are we close?
    De Francesco R; Rice CM
    Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
    Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
    Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.
    Mingorance L; Friesland M; Coto-Llerena M; Pérez-del-Pulgar S; Boix L; López-Oliva JM; Bruix J; Forns X; Gastaminza P
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3451-60. PubMed ID: 24709263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
    Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
    Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A; Rumi MG; Colombo M
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
    Dahari H; Perelson AS
    World J Gastroenterol; 2007 Jun; 13(21):3020-1. PubMed ID: 17589958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.